Pharmacotherapy for benign prostatic hyperplasia — the potential for α1‐adrenoceptor subtype‐specific blockade
- 1 March 1998
- journal article
- review article
- Published by Wiley
- Vol. 81 (S1) , 34-47
- https://doi.org/10.1046/j.1464-410x.1998.0810s1034.x
Abstract
No abstract availableThis publication has 85 references indexed in Scilit:
- Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyPublished by Elsevier ,2003
- Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α1‐adrenoceptor subtypes and in human prostateJournal of Autonomic Pharmacology, 1996
- DoxazosinDrugs, 1995
- Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonistsLife Sciences, 1994
- The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasiaThe Prostate, 1993
- Pharmacologic characterization of cloned α1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtypeEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- Molecular cloning and sequencing of a cDNA encoding a human α1A adrenergic receptorBiochemical and Biophysical Research Communications, 1991
- Bladder Outflow Obstruction Treated with PhenoxybenzamineBritish Journal of Urology, 1982